NR4A1 and neoplasm: Given that hormone receptor expression levels and genomic features such as MAPK mutation may represent biomarkers of endocrine therapy and MEK inhibitor response, histopathological features associated with these molecular events are a candidate strategy for future therapeutic stratification that would not require tumour molecular profiling.